Abstract
The 2019 coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Clinical outcomes, including mortality, are worse in males, older individuals and patients with comorbidities. COPD patients are included in shielding strategies due to their susceptibility to virus-induced exacerbations, compromised pulmonary function and high prevalence of associated comorbidities. Using evidence from basic science and cohort studies, this review addresses key questions concerning COVID-19 and COPD. First, are there mechanisms by which COPD patients are more susceptible to SARS-CoV-2 infection? Secondly, do inhaled corticosteroids offer protection against COVID-19? And, thirdly, what is the evidence regarding clinical outcomes from COVID-19 in COPD patients? This up-to-date review tackles some of the key issues which have significant impact on the long-term outlook for COPD patients in the context of COVID-19.
Abstract
This up-to-date review tackles some of the key issues which have significant impact on the long-term outlook for COPD patients in the context of COVID-19 https://bit.ly/36PKzEO
Footnotes
Provenance: Submitted article, peer reviewed
Conflict of interest: A. Higham reports personal fees from Chiesi, outside the submitted work.
Conflict of interest: A. Mathioudakis reports grants from Boehringer Ingelheim outside the submitted work.
Conflict of interest: J. Vestbo reports personal fees from AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK and Novartis, and grants from Boehringer-Ingelheim, outside the submitted work.
Conflict of interest: D. Singh reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Theravance and Verona, outside the submitted work.
Support statement: This research was supported by the NIHR Manchester Biomedical Research Centre and the North West Lung Centre Charity, Manchester. This report is independent research and the views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Dept of Health. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received June 22, 2020.
- Accepted October 2, 2020.
- Copyright ©ERS 2020.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
